Longeveron Inc.

LGVN

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001721484

E

weakest fifth of 370 graded peers in healthcare

rank 358 of 370; percentile 96.7; sampling error 2.5 points; lower is stronger

A B C D E

E, the bear



Scoreboard

Profitability	D percentile 63.3
Solvency	E percentile 86.5
Growth and financing	D/E percentile 81.8
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $10.3M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	short runway not computable: dilution, distress, fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 17, 2026 216 days before the rescan; latest periodic filing 10-Q received Aug 12, 2026
Last close	$1.38 2026-10-16; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 17, 2026

We are a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Our lead investigational product candidate is laromestrocel, also referred to as Lomecel-B®. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. Laromestrocel possesses broad potential applications across a spectrum of disease areas.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 63.3						
Gross profitability	7.8%	32.3%		78.9	371	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(22.7%)	(6.6%)	19.0	812	2025-12-31
Gross margin stability, five years	17.6 pts	2.8 pts	92.1	242	2025-12-31
Solvency, sleeve percentile 86.5					
Twelve-month failure probability	not computable	0.07%			
liabilities and a nearby cover-page share count are required at 2026-06-30					
Altman Z double-prime	(55.12)	(0.30)	89.7	757	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31					
Current ratio	1.33x	2.96x	83.3	840	2025-12-31
Growth and financing, sleeve percentile 81.8					
Revenue growth, three-year compound	(0.6%)	10.1%	72.4	414	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	(27.9%)	2.1%	91.2	705	2025-12-31
Net share issuance, one year	not computable	2.5%			
two annual share counts are required; found 0					

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 5.9 months

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
353	Biomerica Inc. (BMRA)	95.4	E	
354	ALX Oncology Holdings Inc. (ALXO)	95.7	E	dilution, short runway, degenerate inputs, fortress balance sheet
355	Bolt Biotherapeutics, Inc. (BOLT)	95.9	E	short runway, distress
356	Pfizer Inc. (PFE)	96.2	E	
357	Dare Bioscience, Inc. (DARE)	96.5	E	dilution
358	Longeveron Inc. (LGVN)	96.7	E	short runway
359	Clene Inc. (CLNN)	97.0	E	dilution, distress
360	Agenus Inc. (AGEN)	97.3	E	dilution, short runway
361	Nektar Therapeutics (NKTR)	97.6	E	dilution, short runway
362	Vyome Holdings, Inc. (HIND)	97.8	E	dilution, late filer, fortress balance sheet
363	Sintx Technologies, Inc. (SINT)	98.1	E	dilution, short runway

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	819.9%	8.0%	100
Distance from 52-week high	(83.5%)	(33.0%)	7
EBIT to enterprise value	not computable	(1.7%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	2.01	(0.13)	100

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$10.1M
Operating cash flow, four quarters	-$20.4M
Months of runway	5.9
Days since last periodic filing	68 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	$280,987

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$803,000	2025-12-31	2026-03-17	10-K	26-110664
2	assets	us-gaap:Assets	$10.3M	2025-12-31	2026-03-17	10-K	26-110664
3	net income	us-gaap:NetIncomeLoss	-$22.7M	2025-12-31	2026-03-17	10-K	26-110664
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$18.6M	2025-12-31	2026-03-17	10-K	26-110664
5	assets	us-gaap:Assets	$25.6M	2024-12-31	2026-03-17	10-K	26-110664
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.2M	2025-12-31	2026-03-17	10-K	26-110664
7	gross profit	us-gaap:GrossProfit	$1.9M	2024-12-31	2026-03-17	10-K	26-110664
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.4M	2024-12-31	2026-03-17	10-K	26-110664
9	gross profit	us-gaap:GrossProfit	$221,000	2023-12-31	2025-02-28	10-K	25-029968
10	revenue	us-gaap:Revenues	$709,000	2023-12-31	2024-02-27	10-K	24-017521
11	gross profit	us-gaap:GrossProfit	$497,000	2022-12-31	2024-02-27	10-K	24-017521
12	revenue	us-gaap:Revenues	$1.2M	2022-12-31	2024-02-27	10-K	24-017521
13	gross profit	us-gaap:GrossProfit	$590,000	2021-12-31	2023-03-14	10-K	23-020006
14	revenue	us-gaap:Revenues	$1.3M	2021-12-31	2023-03-14	10-K	23-020006
15	current assets	us-gaap:AssetsCurrent	$5.5M	2025-12-31	2026-03-17	10-K	26-110664
16	current liabilities	us-gaap:LiabilitiesCurrent	$4.1M	2025-12-31	2026-03-17	10-K	26-110664
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$132.3M	2025-12-31	2026-03-17	10-K	26-110664
18	operating income	us-gaap:OperatingIncomeLoss	-$23.3M	2025-12-31	2026-03-17	10-K	26-110664

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	book equity	us-gaap:StockholdersEquity	$5.7M	2025-12-31	2026-03-17	10-K	26-110664
20	liabilities	us-gaap:Liabilities	$4.6M	2025-12-31	2026-03-17	10-K	26-110664
21	operating income	us-gaap:OperatingIncomeLoss	-$18.0M	2022-12-31	2024-02-27	10-K	24-017521
22	interest expense	us-gaap:InterestExpense	$1.4M	2022-12-31	2023-03-14	10-K	23-020006
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$245,000	2025-12-31	2026-03-17	10-K	26-110664
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$13.9M	2024-12-31	2026-03-17	10-K	26-110664
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$655,000	2024-12-31	2026-03-17	10-K	26-110664
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$19.0M	2023-12-31	2025-02-28	10-K	25-029968
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$301,000	2023-12-31	2025-02-28	10-K	25-029968
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$14.0M	2022-12-31	2024-02-27	10-K	24-017521
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$569,000	2022-12-31	2024-02-27	10-K	24-017521
30	assets	us-gaap:Assets	$12.1M	2023-12-31	2025-02-28	10-K	25-029968
31	assets	us-gaap:Assets	$27.4M	2022-12-31	2024-02-27	10-K	24-017521

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.